Stock Events

Harpoon Therapeutics 

$22.95
33
+$0.01+0.04% Friday 20:59

Statistics

Day High
-
Day Low
-
52W High
22.97
52W Low
3.11
Volume
807,009
Avg. Volume
1,415,844
Mkt Cap
388.6M
P/E Ratio
-9.48
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25MarExpected
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q2 2023
Q3 2023
Next
-3.2
-2.11
-1.01
0.08
Expected EPS
-0.64
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HARP. It's not an investment recommendation.

Analyst Ratings

27.25$Average Price Target
The highest estimate is $40.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
40%
Hold
60%
Sell
0%

About

Biotechnology
Health Technology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Show more...
CEO
Gerald McMahon
Employees
45
Country
US
ISIN
US41358P1066
WKN
000A2PCBT

Listings